Lupin’s net profit increased by 88% to ₹1,468.67 crore in the fourth quarter from ₹782.38 crore in the previous year.
Revenue growth for the quarter stood at 32% to ₹7,474.66 crore compared to ₹5,667.13 crore last year.
Lupin’s earnings before interest, tax, depreciation and amortisation (EBITDA) increased 88% as well to ₹2,485.58 crore from ₹1,321.17 crore in the fourth quarter of the previous fiscal.
Its margins expanded to 33.3% from 23.3% in the year-ago period.
The drugmaker’s sales in the US market were at their highest ever. The US market sales were at $371 million compared to $250 million in the year-ago period and also higher than the $350 million reported in the December quarter.
Lupin’s India market sales increased by 11% to ₹1,908.2 crore from ₹1,711.3 crore last year. However, it declined sequentially from the ₹2,038.7 crore figure.
Other developed markets sales grew by 7.1% to ₹845.3 crore from ₹788.9 crore in the previous year. Emerging markets sales increased by 49.2% to ₹990.6 crore from 663.9 crore last year.
The Active Pharmaceutical Ingredient (API) segment grew by 7.6% to ₹249.1 crore from ₹231.5 crore in the year-ago period.
Lupin’s board also approved a dividend of ₹18 per share of the face value ₹2 each for the financial year 2026, subject to declaration by the members of upcoming Annual General Meeting. The dividend would be paid within 30 days from the date of declaration.
40 analysts have coverage on Lupin, of which 28 have a “buy” rating, eight say “hold” and four have a “sell” rating on the stock.
Lupin shares ended the previous session 0.8% higher at ₹2,462 apiece. The stock has risen 7.3% in the past month and 17% this year, so far.
Also Read: Pidilite Industries shares in focus after stellar Q4 results beat street estimates across parameters
